Kronos Bio, Inc. (NASDAQ:KRON – Free Report) insider Christopher Dinsmore sold 6,634 shares of the stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $1.75, for a total transaction of $11,609.50. Following the sale, the insider now owns 278,367 shares of the company’s stock, valued at approximately $487,142.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Kronos Bio Price Performance
Shares of NASDAQ:KRON opened at $1.99 on Friday. Kronos Bio, Inc. has a 12 month low of $1.20 and a 12 month high of $5.74. The company’s 50-day moving average price is $1.70 and its two-hundred day moving average price is $1.74.
Kronos Bio (NASDAQ:KRON – Free Report) last issued its quarterly earnings data on Wednesday, May 10th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). The business had revenue of $1.22 million for the quarter, compared to analysts’ expectations of $11.25 million. On average, sell-side analysts expect that Kronos Bio, Inc. will post -1.91 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of KRON. Swiss National Bank boosted its stake in shares of Kronos Bio by 7.8% in the 1st quarter. Swiss National Bank now owns 40,000 shares of the company’s stock valued at $289,000 after purchasing an additional 2,900 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Kronos Bio in the 1st quarter valued at about $25,000. MetLife Investment Management LLC boosted its stake in shares of Kronos Bio by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 24,534 shares of the company’s stock valued at $177,000 after purchasing an additional 9,055 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Kronos Bio by 1.0% in the 1st quarter. BlackRock Inc. now owns 3,401,730 shares of the company’s stock valued at $24,593,000 after purchasing an additional 32,054 shares during the last quarter. Finally, Ergoteles LLC bought a new position in shares of Kronos Bio in the 1st quarter valued at about $231,000. Institutional investors own 56.21% of the company’s stock.
Kronos Bio Company Profile
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
Recommended Stories
- Five stocks we like better than Kronos Bio
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.
